Julia Bates
Pain Medicine · Winston Salem, NCNPI 1720350887
Payments from drug & device makers
Across 230 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Collegium Pharmaceutical, Inc.$620
- Pfizer$370
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$218
- Novo Nordisk$195
- Lilly USA, LLC$175
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,792100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,028 |
| Collegium Pharmaceutical, Inc. | 35 | $620 |
| Pfizer | 28 | $370 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $218 |
| Novo Nordisk | 12 | $195 |
| Lilly USA, LLC | 11 | $175 |
| Amgen | 7 | $171 |
| Forte Bio-pharma LLC | 3 | $103 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $100 |
| Scilex Pharmaceuticals Inc. | 6 | $83 |
| Bayer | 4 | $70 |
| Ironwood Pharmaceuticals, Inc | 3 | $69 |
| GSK | 4 | $67 |
| Medtronic | 1 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Orexo US, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Tonix Medicines, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Painteq LLC | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Boston Scientific | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $15 |
| Novartis | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,792 in reported general payments places this provider in the 45th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 667 | $28,537 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 581 | $22,489 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 149 | $22,303 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 31 | $20,624 |
| OzempicSemaglutide | 21 | $20,589 |
| LinzessLinaclotide | 28 | $15,851 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,067 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $10,170 |
| EliquisApixaban | 12 | $8,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,619 |
| Oxycodone Hcl | 434 | $7,576 |
| Lidocaine | 29 | $6,320 |
| Xtampza ErOxycodone Myristate | 11 | $5,268 |
| Morphine Sulfate ErMorphine Sulfate | 134 | $3,062 |
| Gabapentin | 193 | $2,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $370 | $22,40626 claims |
| Orexo US, Inc.Zubsolv | $50 | $20,62431 claims |
| Novo NordiskOzempic | $195 | $20,58921 claims |
| AbbVieLinzess | $1,028 | $15,85128 claims |
| GSKTrelegy Ellipta | $67 | $7,61912 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $620 | $5,26811 claims |
| AstraZenecaSymbicort | $18 | $2,72712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Winston Salem
- Leonardo KapuralWinston Salem$4.1M
- James NorthWinston Salem$3.7M
- Richard RauckWinston Salem$1.7M
- Christopher GilmoreWinston Salem$1.3M
- Jeffrey PeacockWinston Salem$553K
- Daniel BintrimWinston Salem$39K
- Lauren BeaverWinston Salem$11K
- Binit ShahHuntersville$863K
- Courtney AumanJacksonville$210K
- Javid BakshAsheville$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.